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Targeting the latent cytomegalovirus reservoir
with an antiviral fusion toxin protein
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Reactivation of human cytomegalovirus (HCMV) in transplant recipients can cause life-
threatening disease. Consequently, for transplant recipients, killing latently infected cells
could have far-reaching clinical beneﬁts. In vivo, myeloid cells and their progenitors are an
important site of HCMV latency, and one viral gene expressed by latently infected myeloid
cells is US28. This viral gene encodes a cell surface G protein-coupled receptor (GPCR) that
binds chemokines, triggering its endocytosis. We show that the expression of US28 on the
surface of latently infected cells allows monocytes and their progenitor CD34þ cells to be
targeted and killed by F49A-FTP, a highly speciﬁc fusion toxin protein that binds this viral
GPCR. As expected, this speciﬁc targeting of latently infected cells by F49A-FTP also robustly
reduces virus reactivation in vitro. Consequently, such speciﬁc fusion toxin proteins could
form the basis of a therapeutic strategy for eliminating latently infected cells before
haematopoietic stem cell transplantation.
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H
uman cytomegalovirus (HCMV) is a species-speciﬁc
b-herpesvirus that has characteristic lytic and latent
stages to its life cycle1. It is a ubiquitous pathogen,
infecting 50–90% of populations, depending on socioeconomic
factors, maintaining a lifelong infection in the carrier2. Primary
HCMV infection is normally well controlled by a robust humoral
and T cell-based immune response and, consequently, it is often
asymptomatic in healthy individuals. Despite this, primary
HCMV infection is never cleared by the immune system and
results in a lifelong viral persistence that is underpinned by the
ability of the virus to undergo latent infection. Although sporadic
reactivation from latency likely routinely occurs in vivo3, it is
asymptomatic in healthy individuals. However, virus reactivation,
like primary infection, poses a severe clinical threat to
immunocompromised individuals, such as transplant recipients
and patients with AIDS4.
Although HCMV has a wide cell tropism for the lytic life cycle,
its latent life cycle appears more restricted. One site of latent
carriage is in cells of the early myeloid lineage that includes
CD34þ progenitor cells and CD14þ monocytes4. In these
latently infected cells, maintenance of viral genome is associated
with expression of a relatively small number of latency-associated
viral genes and no infectious virus is produced. This in itself likely
aids these sites of latency to escape host immune surveillance5. It
is now also clear that, in healthy HCMV-positive donor cells,
differentiation of CD14þ monocytes and CD34þ progenitors
to dendritic cells and macrophages triggers virus reactivation
from latency3,6–8 and that this differentiation-dependent reacti-
vation of latent virus in the myeloid lineage is mediated by
changes in post-translational modiﬁcation of histones around
the viral MIEP (major immediate-early promoter). This drives
viral major immediate-early (IE) gene expression, resulting in
reactivation of the viral lytic gene cascade and the production of
infectious virions7. Latent infection is, therefore, a key aspect of
viral persistence and latently infected cells are a clear threat to the
immunocompromised. Despite this, there have only been few
reports describing the therapeutic targeting of latently infected
cells9.
For this reason, much attention has been drawn to viral gene
products expressed during HCMV latency and the possibility that
they might alter the phenotype of the latently infected cell that
can then be exploited for novel antiviral therapies5. For instance,
latent infection has been shown to induce changes in cellular
RNA expression10–13, the cellular secretome14 as well as cell
surface protein expression9. These changes are likely mediated by
expression of the HCMV latency-associated genes15,16. A number
of these have been detected in naturally latently infected cells
from healthy seropositive donors, including UL84, UL81-82ast,
UL138, UL144, LUNA, UL111A, RNA4.9 and US28 (refs 16–20).
Although the functions of many of these latency-associated gene
products are becoming better established, their roles in latency
speciﬁcally are still unclear.
Allogeneic haematopoietic stem cell transplants (allo-HSCTs),
for example, from granulocyte colony-stimulating factor
(CSF)-mobilized donors, are routinely used as a treatment for
several high-risk leukaemias and other nonmalignant diseases.
Peripheral blood stem cells are now one of the most common
sources of stem cells for allo-HSCT and comprise multipotent
CD34þ cells that expand and differentiate to reconstitute
the immune system. However, this differentiation can also
result in HCMV reactivation in up to 80% of allo-HSCT patients,
if not treated with antivirals21. Although prophylactic treatment
with antivirals such as ganciclovir and foscarnet keeps CMV
disease incidence below 10% in these patients, ganciclovir
mediated neutropenia can lead to increased mortality from
bacterial and fungal infections22. Consequently, the reduction in
latent HCMV load in HSCTs could have far-reaching clinical
beneﬁts23–27.
US28 is one of four G protein-coupled receptor (GPCR)
homologues encoded by HCMV28. All four receptors are
expressed during lytic infection29,30, but only US28 mRNA has
been detected in models of latent infection31–33 as well as
naturally latently infected monocytes34. Similarly, recent work
from Humby and O’Connor35 has shown that US28 is important
to establish latency in CD34þ cells. US28 is also the best
characterized of these virus-encoded receptors; it binds both CC
and CX3C chemokines36 and this ligand binding affects US28
constitutive signalling37,38. This appears to promote proliferative
signals during lytic HCMV infection that, therefore, have been
linked to vascular diseases and potential oncomodulatory
effects39–41. US28 has also been shown to heteromerize with
the other HCMV-encoded GPCRs UL33 and UL78 that inhibits
constitutive US28 activation of nuclear factor-kB42.
Fusion toxin proteins (FTPs) exploit high-afﬁnity receptor–
ligand interactions to direct cytotoxic molecules to target cells,
and have shown success as novel cancer therapies43,44. Moreover,
the technique has a great potential as a treatment for other
indications, such as infectious diseases, where pathogen-encoded
targets provide superior speciﬁcity45. Recently, a novel fusion
toxin protein (F49A-FTP) has been described that targets and
kills cells lytically infected with HCMV46. F49A-FTP is based on
the soluble extracellular domain of the US28 ligand CX3CL1 (also
known as fractalkine) and binds US28 with high afﬁnity
compared with the cellular CX3CL1 receptor, CX3CR1. After
binding US28, F49A-FTP is internalized and mediates cell killing
via a recombinant Pseudomonas exotoxin-A motif.
Here, we demonstrate that F49A-FTP is able to kill monocytes
and CD34þ progenitor cells that are experimentally latently
infected with HCMV and that this killing is dependent on US28
expression. Furthermore, we show that this killing is effective at
reducing viral load in naturally latently infected CD14þ
monocytes. Consistent with this reduction in latent load, this
FTP robustly reduces the frequency of virus reactivation from
experimentally and naturally latently infected cells. These results
are, therefore, proof of principle that F49A-FTP can purge the
latent load of HCMV in haematopoietic stem cell grafts that
could form the basis for a novel approach to greatly reduce the
clinical threat of HCMV-positive grafts in the stem cell transplant
setting.
Results
F49A-FTP kills myeloid cells that express US28 in isolation. It
was previously shown that F49A-FTP is able to kill ﬁbroblast cells
that were lytically infected with HCMV46. To start, we wanted
to demonstrate that this cytotoxity was due solely to US28
expression and not because of other factors associated with viral
infection. Consequently, we infected human foreskin ﬁbroblasts
(HFFs) with two isolates of HCMV; the wild type, clinal isolate,
Titan strain of HCMV or Titan with a deletion in the US28 gene
(Titan-DUS28), both of which have a green ﬂuorescent protein
(GFP)-tagged UL32 gene. Cell cultures were then treated with
F49A-FTP for 72 h before infected cells were visualized by
ﬂuorescence microscopy. F49A-FTP was able to kill HFFs
infected with wild-type Titan HCMV but not the corresponding
US28-deletion virus (Fig. 1).
In addition to lytic infection, we also wanted to assess the
ability of F49A-FTP to kill cells in which HCMV would normally
establish latent infection. To do this, we used THP-1 cells, a
monocyte-like cell line and can be used as a model of HCMV
latency47,48. THP-1 cells were transduced with lentiviral vectors
to express haemagglutinin (HA)-tagged US28 (HA-US28) in
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isolation. After this, puromycin selection was used to generate a
cell population expressing HA-US28, and HA-US28 expression
was conﬁrmed by immunoblot analysis (Fig. 2a). Incubation of
these THP-1 cells with F49A-FTP for 48 h showed that F49A-FTP
efﬁciently killed US28-expressing THP-1 cells but not mock-
transduced cells (Fig. 2b).
Latently infected monocytes express cell surface US28. On the
basis that F49A-FTP is able to kill myeloid cells expressing US28
in isolation, we reasoned that this could enable us to target
latently infected myeloid cells that are known to express US28
mRNA34,49. However, in order for this approach to work, it was
important to conﬁrm that US28 protein is expressed and
trafﬁcked to the cell surface during latent infection of CD14þ
monocytes. Because of the lack of available anti-US28 antibodies
capable of detecting US28 in latent cells, we were unable to stain
latently infected cells directly. Consequently, we turned to
radiolabelling assays. We latently infected CD14þ monocytes
with an HCMV TB40E isolate with an SV40-GFP tag
(SV40-GFP-TB40E)50 that allows the short-term detection of
GFP-tagged latently infected cells9 and sorted GFP-positive
monocytes to enrich for a population of latently infected
monocytes by ﬂuorescence-activated cell sorting. We conﬁrmed
by reverse transcriptase-quantitative PCR (RT-qPCR) analysis of
HCMV gene expression that these cells were latent (Supple-
mentary Fig. 1a). RT-qPCR of these cells before and after sorting
showed high levels of expression of UL138 mRNA, a known
latency-associated gene, concomitant with low levels of lytic
transcripts (IE and UL99) compared with reactivated mature
dendritic cells that resulted in a characteristic lytic transcription
proﬁle, with a switch to high levels of lytic IE and late RNAs
(Supplementary Fig. 1a), consistent with previous studies51–55.
We also analysed viral IE and late protein expression in these cells
(Supplementary Fig. 1d) and observed no IE or UL99 protein
expression. Similarly, no infectious virus could be isolated from
these latently infected cells (Supplementary Fig. 1e), as expected.
In contrast, reactivation of these latently infected monocytes
resulted in detectable IE and UL99 expression (Supplementary
Fig. 1d) as well as production of infectious virions (Supple-
mentary Fig. 1e).
We then measured the afﬁnity of sorted, latently infected cells
for 125iodine-radiolabelled CX3CL1, which is a high-afﬁnity
ligand of both US28 (ref. 36) and the endogenous receptor
CX3CR1, that is expressed on monocytes. Figure 3a,b show that
latently infected monocytes showed a higher binding afﬁnity for
CX3CL1 compared with uninfected monocytes, similar to the
increase observed in US28 expressing Cos 7 cells compared with
COS-7 cells expressing CX3CR1. We considered that although
this result could result from latency-associated expression of
US28, formally it could also have been because of increased
expression of CX3CR1, perhaps induced by latent infection. To
differentiate between these two possibilities, we performed
RT-qPCR analysis over several time points post infection,
measuring relative US28 and CX3CR1 expression (Fig. 3c,d).
This showed that US28 is expressed from 1 day post infection in
our model of latency. It also showed that, although latent viral
infection does cause a minor increase in CX3CR1 expression, at 5
days post infection, when the binding assays were carried out in
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Figure 1 | F49A-FTP kills lytically infected cells because of their expression of US28. Human foreskin ﬁbroblast cells (HFFs) were infected with either
HCMV Titan wild-type or HCMV Titan-DUS28 at an MOI of 0.1. Both viral isolates have a UL32-GFP tag, causing infected cells to appear green by
ﬂuorescence microscopy. Cultures were then either mock-treated with PBS or treated with 5 108M F49A-FTP for 72 h and observed by ﬂuorescence
microscopy. (a) Representative images of the virally infected cultures with or without F49A-FTP. (b) A graphical representation of these data. Cell numbers
were quantiﬁed by Hoechst staining cell nuclei, and the percentage of infected (green) cells is shown as a percentage of the control. White bars indicate
50mm scale. Means and error bars (showing s.d.) were generated from three independent experiments. Statistical analyses were carried out using a paired
two-tailed t-test and ***P¼0.001 were considered signiﬁcant.
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Figure 2 | F49A-FTP kills monocyte-like THP-1 cells that express US28.
THP-1 cells expressing HA-US28 were generated by lentiviral transduction
and puromycin selection. (a) Western blots of cell lysates from transduced
THP-1 cells against the N-terminal HA tag on HA-US28, control cells were
mock transduced. (b) THP-1 cells expressing HA-US28, or control cells,
were treated with 5 10 8M F49A-FTP for 48 h. Cell death was quantiﬁed
by Trypan blue staining. Means and error bars (showing s.d.) were
generated from seven independent experiments. Statistical analyses were
carried out using a paired two-tailed t-test and ***P¼0.001 were
considered signiﬁcant.
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Fig. 3a, CX3CR1 showed no signiﬁcant increase in expression.
Taken together, these data are consistent with the view
that US28 is expressed on the cell surface of latently infected
monocytes.
F49A-FTP kills experimentally latently infected monocytes.
Knowing that latently infected cells do, indeed, bind CX3CL1
with higher afﬁnity than control monocytes, as a result of US28
expression, we next analysed whether F49A-FTP could kill
latently infected cells. To do this, we experimentally infected
CD14þ monocytes with SV40-GFP tagged HCMV50, conﬁrmed
latency by RT-qPCR (see Supplementary Fig. 1b) and tested the
effect of treatment with F49A-FTP. We based the concen-
tration of F49A-FTP used (5 10 8M) and the incubation time
of 72 h on pilot titration experiments on latently infected
monocytes (Supplementary Fig. 2).
After 72 h of treatment with F49A-FTP, we observed a
signiﬁcant loss of GFP-positive, latently infected monocytes
(Fig. 4a). In order to ensure that these observations were because
of the killing of latently infected cells, and not just a result of
silencing of the SV40-GFP expression cassette, we next removed
F49A-FTP from these cultures and replaced it with fresh media
containing cytokines followed by lipopolysaccharide (LPS) in
order to stimulate differentiation and maturation to mature
dendritic cells (mDCs), thereby resulting in reactivation of any
remaining latent viral genomes. As the SV40-GFP cassette in the
viral genome is also expressed during lytic infection50, we again
quantiﬁed the number of GFP-expressing mDCs resulting from
reactivation of GFP-tagged virus. Figure 4b shows that the
percentage of GFP-positive CD14þ monocyte-derived mDCs
was also reduced in F49A-FTP-treated cultures. Finally, we co-
cultured these CD14þ monocyte-derived mDCs with HFFs and
quantiﬁed foci of viral IE expression by immunoﬂuorescent
staining in the ﬁbroblasts as a measure of the reactivation of
infectious virions (Fig. 4c) and again observed that F49A-FTP
treatment resulted in a signiﬁcant reduction in the amount of
reactivated infectious virus. Taken together, these data show that
F49A-FTP can target and reduce the number of experimentally
latently infected CD14þ monocytes thus reducing subsequent
reactivation of latent virus after differentiation and maturation.
If this targeting of latently infected cells was speciﬁcally because
of US28 expression, F49A-FTP should be less effective against
monocytes infected with a US28 deletion virus. To address this,
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Figure 3 | Latently infected monocytes have high afﬁnity for CX3CL1 that indicates cell surface US28 expression. Homologous competition binding on
COS-7 cells and monocytes. (a) Binding of 125I-CX3CL1 to uninfected (white symbols) and sorted, GFP-positive (latent) HCMV-infected monocytes (black
symbols). The data are normalized to maximal binding on infected cells. Error bars indicate s.e.m. for ﬁve independent biological replicates. (b) Binding of
125I-CX3CL1 to transiently transfected COS-7 cells expressing US28 (black) and CX3CR1 (white symbols). The data are normalized to maximal speciﬁc
binding on US28-expressing cells. Error bars indicate s.e.m. for three independent biological replicates. (c) RT-qPCR analysis of CX3CR1 mRNA expression
in monocytes latently infected at an MOI of 5, with SV40-GFP-TB40E, or monocytes treated with UV-inactivated virus, relative to an uninfected control.
UV-inactivated virus samples were taken 1 day post infection. Means and s.d. values are shown from three measurements and normalized to GAPDH.
(d) RT-qPCR analysis of US28 mRNA expression in monocytes latently infected at an MOI of 5, with SV40-GFP-B40E, relative to mRNA harvested
immediately after infection (input control). Means and s.d. values are shown from three measurements and normalized to GAPDH. Statistical analyses
were carried out using a paired two-tailed t-test and P values expressed as *P¼0.05 or ***P¼0.001 were considered signiﬁcant.
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we employed the Titan-DUS28 (ref. 56) that also contains a
UL32-GFP tag that is expressed to high levels upon lytic
infection/reactivation. We established latency in monocytes
with wild-type Titan or Titan-DUS28, treated the latently
infected cells with F49A-FTP and then reactivated cells by
differentiation and maturation and quantiﬁed lytic reactivation
directly by detection of UL32-GFP expression in these mDCs
(Fig. 4d). We also quantiﬁed the production of infectious virus
from these mDCs by co-culturing them with indicator ﬁbroblasts
and staining for viral IE reactivation foci (Fig. 4e). Although
treatment of monocytes latently infected with Titan wild-type
virus with F49A-FTP showed a reduction in the frequency
of UL32-GFP reactivating cells (Fig. 4d) and reactivation of
infectious virus from these cells (Fig. 4e), monocytes infected with
Titan-DUS28 show no such decreases (Fig. 4d,e). This conﬁrmed
that F49A-FTP selectively kills latently infected cells based on
US28 expression.
It should be pointed out that this control experiment is,
necessarily, an imperfect one as US28 expression is known to be
necessary for the maintenance of latency; US28-deleted viruses
undergo lytic infection in undifferentiated CD34þ cells and
monocytes35. Nevertheless, lytically infected cells are also killed
by F49A-FTP when expressing US28 (see Fig. 1), and the fact that
monocytes infected with Titan-DUS28 are not killed by F49A-
FTP still supports the notion that F49A-FTP kills latently infected
monocytes in a US28-dependent manner.
In addition, we considered that killing by F49A-FTP could also
be because of US28 being carried into the cell by infectious
virions. In order to control for this, we delayed F49A-FTP
treatment of experimentally infected monocytes by 1, 3, 5 and 7
days post infection that should allow time for virion-delivered
US28 to be degraded. We found that treatment was as effective at
clearing latently infected cells at day 7 compared with day 1
(Supplementary Fig. 3a). Finally, we tested F49A-FTP efﬁcacy
against cultures that were experimentally infected at low multi-
plicity of infection (MOI); F49A-FTP only marginally lost
its efﬁcacy when treating cultures with few latently infected
monocytes (Supplementary Fig. 3b).
F49A-FTP also kills experimentally infected CD34þ cells. As
CD34þ progenitor cells, a major component of HSCTs, are also
sites of latent carriage of HCMV in vivo, we repeated these
analyses with experimentally latently infected CD34þ progenitor
cells. Firstly, we conﬁrmed these cells were, indeed, latently
infected. Consistent with previous studies54, infected CD34þ
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Figure 4 | F49A-FTP kills experimentally latently infected monocytes, reducing HCMV reactivation events. CD14þ peripheral blood monocytes were
isolated and experimentally infected at an MOI of 5 with HCMV SV40-GFP-TB40E wild type that led to a mean average of 10.9% latently infected cells.
After 24 h, F49A-FTP was added to monocyte cultures, and incubated for 72 h. Changes in the number of GFP-positive cells was observed by ﬂuorescence
microscopy and compared with a mock-treated latently infected cell controls that was set at 100% (a). These monocytes were then differentiated using
granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation followed by LPS treatment to mature dendritic cells
(mDCs). Similarly, changes in the percentage of GFP-positive mDCs were then measured (b). Finally, the cells shown in b were co-cultured with
ﬁbroblasts for 2 weeks and the numbers of IE foci were counted (c). Means and error bars (showing s.d.) were generated from ﬁve independent
experiments. (d) Monocytes were isolated and experimentally infected with either HCMV Titan wild-type or HCMV Titan with a US28 deletion at an MOI
of 5. Cultures were then either mock-treated with PBS or treated with F49A-FTP for 3 days and then reactivated by differentiation into mDCs as above.
Using the UL32-GFP tag on these viral isolates, reactivated dendritic cells were then counted and compared with levels of reactivation of monocytes
infected with Titan wild-type virus in the absence of drug that was set to 100%. (e) After co-culture with reporter ﬁbroblast cells, incubation for 2 weeks
and staining for IE, reactivation events were quantiﬁed. Means and error bars (showing s.d.) were generated from three independent experiments.
Statistical analyses were carried out using a paired two-tailed t-test and P values expressed as *P¼0.05, **P¼0.01 or ***P¼0.001.
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cells showed a proﬁle of viral transcription associated with
latency; a low level of lytic IE RNA compared with much higher
levels of latency-associated UL138 RNA (Supplementary Fig. 1c)
and, importantly, an inability to culture infectious virus from the
latently infected cells (Supplementary Fig. 1e). In contrast,
differentiation and maturation of these cells to mature CD34þ
derived DCs resulted in a characteristic lytic transcription proﬁle
with a switch to high levels of lytic IE compared with UL138
(Supplementary Fig. 1c), as well as efﬁcient virus production
(Supplementary Fig. 1e).
Once again, as with latently infected CD14þ monocytes, we
observed that F49A-FTP reduced the number of GFP-expressing
latently infected CD34þ cells (Fig. 5a), reduced the number of
GFP-expressing CD34þ derived mDCs resulting from reactiva-
tion of GFP-tagged virus (Fig. 5b) and signiﬁcantly reduced the
amount of reactivated infectious virus capable of reinfecting HFFs
in co-culture (Fig. 5c).
F49A-FTP can kill naturally latently infected monocytes. Our
data, so far, argue that F49A-FTP is able to target and kill
experimentally latently infected CD14þ monocytes and CD34þ
progenitor cells, resulting in a profound reduction in virus
reactivation events after differentiation and maturation of latently
infected cells. However, a key question is whether such a treat-
ment can also target naturally latent cells and prevent reactivation
of infectious virus. Consequently, we isolated latently infected
monocytes from healthy seropositive donors and treated them
with F49A-FTP. In order to assess any reduction in naturally
latent load in these cells, we differentiated and matured any
surviving latently infected monocytes, after F49A-FTP treatment,
to mDCs to induce virus reactivation and subsequently measured
reactivation of infectious virus by co-culture with HFF indicator
cells, followed by immunoﬂuorescent staining for IE-positive foci
in these ﬁbroblast co-cultures. Figure 6 shows that treatment of
naturally latently infected monocytes with F49A-FTP also causes
a strong reduction in viral reactivation from these fusion toxin-
treated naturally latent cells.
Discussion
HCMV can establish latent infection in early myeloid lineage
cells4, a major cell type present in HSCTs. The presence of latent
HCMV in allogenic HSCTs can lead to serious medical
complications21, accepted to be because of reactivation of latent
cytomegalovirus after differentiation of these early myeloid cells
to terminally differentiated macrophages and DCs. Currently,
there are only few examples of strategies to selectively kill
HCMV-infected early myeloid lineage cells9; this killing of
latently infected cells, with the vinca alkaloid vincristine, can
reduce viral reactivation events that would likely reduce their
threat to any immunocompromised allo-HSCT recipient after
transplant. However, the high toxicity of vincristine would likely
be a serious barrier to such use therapeutically.
Recently, a rationally designed FTP named F49A-FTP has been
developed that exploits cell surface expression of US28 during
lytic infection to kill lytically infected ﬁbroblast cells46. We have
conﬁrmed that the anti-HCMV activity of F49A-FTP is US28
speciﬁc by ectopic expression of US28 in THP-1 monocytic cells
as well as demonstrating a loss of efﬁcacy against both HFFs and
monocytes that were infected with a US28-deletion isolate.
Interestingly, we and others have shown that US28 mRNA is
also expressed in latently infected early myeloid lineage cells,
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Figure 5 | F49A-FTP kills experimentally latently infected CD34þ progenitor cells, reducing HCMV reactivation events. CD34þ progenitor cells were
experimentally infected with SV40-GFP-TB40E at an MOI of 5 that led to a mean average of 8.5% of cells latently infected. After 24 h, F49A-FTP was
added to CD34þ cell cultures and incubated for 72 h. Changes in the number of GFP-positive latent cells were analysed by ﬂuorescence microscopy and
compared with a mock-treated control that was set at 100% (a). These CD34þ cells were then differentiated to mature dendritic cells and changes in the
percentage of GFP-positive mature dendritic cells were measured (b). Finally, the cells shown in b were co-cultured with ﬁbroblasts for 2 weeks and the
number of IE foci were counted (c). Means and error bars (showing s.d.) were generated from three independent experiments. Statistical analyses were
carried out using a paired two-tailed t-test and P values expressed as *P¼0.05, **P¼0.01 or ***P¼0.001.
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Figure 6 | F49A-FTP kills naturally latently infected monocytes, reducing
reactivation events. 1.2 108 blood monocytes were isolated from CMV-
positive blood donors. Half of these cells were incubated with F49A-FTP for
72h. Monocytes were then differentiated using granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation
followed by LPS treatment. Monocyte-derived, mature dendritic cells (reacti-
vated latent monocytes) were then co-cultured with ﬁbroblasts for 3 weeks,
and the numbers of reactivated IE foci were detected by immunoﬂuorescent
staining. Means and error bars (showing s.d.) were generated from three
independent experiments. Statistical analyses were carried out using a paired
two-tailed t-test and P values expressed as *P¼0.05.
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arguing that this HCMV-encoded, cell surface GPCR is likely
expressed at the protein level during latency34,35,49. Using RT-
qPCR and radiolabelling afﬁnity assays, we have conﬁrmed that
US28 protein is expressed and present on the cell surface of
latently infected CD14þ monocytes and this led us to ask
whether this would make these latently infected cells potential
targets for killing using the US28-speciﬁc fusion toxin protein,
F49A-FTP. As expected, treatment of experimentally latently
infected CD14þ monocytes and CD34þ progenitor cells
with F49A-FTP led to a reduction in latently infected cells, as
measured by decreases in GFP-expressing latent cells after
infection with a GFP-tagged HCMV50. We also conﬁrmed that
this reduction in GFP-positive cell number was because of cell
killing of GFP-expressing cells rather than suppression of GFP
expression in these latently infected cells, as differentiation and
maturation of these F49A-FTP-treated cells to trigger reactivation
of any viable latent virus also showed a profound reduction in
virus reactivation. Finally, we conﬁrmed that naturally latent
cells were also targeted by F49A-FTP by demonstrating that
F49A-FTP treatment of naturally latently infected monocytes
also reduced the number of reactivation events after their
differentiation and maturation.
Based on these observations, we suggest that such a fusion -
toxin protein treatment, targeting US28, could act as the basis for
a treatment to reduce the clinical threat of HCMV reactivation
after allo-HSCTs. Additionally beneﬁcial, as infectious virus is not
produced during latency, resistance to F49A-FTP because of
selection of replicating, drug-resistant mutants is unlikely to
occur during treatment of latently infected cells. Given that
CX3CR1, a low-afﬁnity receptor for F49A-FTP, is expressed on a
number of cell types, we would not envisage treatment of patients
directly with F49A-FTP. Instead, we think such a therapeutic
could be developed to purge latently infected cells from grafts
before engraftment; we believe this could include stem cells as
well as, potentially, solid organs.
Although F49A-FTP treatment of experimentally or naturally
latently infected cells did not completely ablate all reactivation
events, we believe that there are a number of possible avenues to
improve F49A-FTP efﬁcacy. We chose a concentration of
5 10 8M F49A-FTP and an incubation period of 72 h as our
pilot experiments in experimentally infected monocytes indicated
that these were the minimum dose and time required to
clear latent HCMV most efﬁciently while minimizing killing of
uninfected monocytes (Supplementary Fig. 2). However, our
analyses showed that higher concentrations of F49A-FTP could
potentially be used especially in CD34þ cells that showed
no signs of cell death at antivirally active concentrations of
F49A-FTP (Supplementary Fig. 4). Similarly, the recent solution
of the US28 crystal structure in complex with CX3CL1 (ref. 57)
may allow for further reﬁnements to F49A-FTP to increase the
selectivity of F49A-FTP for US28 and therefore the efﬁcacy of
F49A-FTP against naturally latently infected tissue.
In summary, we have demonstrated that latently infected early
myeloid cells express US28 that can be targeted by the FTP F49A-
FTP. This results in killing of both experimentally and naturally
latently infected myeloid cells and the subsequent reduction of
HCMV reactivation events. These ﬁndings are proof of principle
that F49A-FTP can reduce the latent load of HCMV in early
myeloid cells that we believe could form the basis for an approach
to reduce the clinical threat of HCMV-positive grafts in HSCTs.
Methods
Cell culture and viruses. HFF cells (ATCC, 86031405) were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% inactivated fetal
bovine serum (PAA) and penicillin/streptomycin (Sigma). Primary CD14þ
monocytes were isolated from apheresis cones (NHS blood) using Lymphoprep
(Stemcell Technologies) density gradient centrifugation, followed by magnetic-
activated cell sorting using CD14þ magnetic beads (Miltenyi Biotec)58 and
cultured in X-Vivo15 (Lonza) at 37 C in 5% CO2. For experimental infection
models, monocytes were incubated with virus at an MOI of 5 for 3 h at room
temperature with rocking. Virus media were then removed and cells were washed
twice in phosphate-buffered saline (PBS) before fresh X-Vivo15 was replaced.
F49A-FTP was generated as described in Spiess et al.46; brieﬂy, F49A-FTP was
produced in Escherichia coli as inclusion bodies that were isolated and F49A-FTP
was puriﬁed by size exclusion chromatography. After treatment with F49A-FTP,
monocytes were washed and differentiated to immature dendritic cells by
granulocyte-macrophage CSF and interleukin-4 (Peprotech) stimulation at
1,000Uml 1 for 5 days of incubation. Mature dendritic cells were produced by
stimulation for 2 days with LPS (Sigma) at 500 ngml 1. Primary CD34þ
progenitor cells were isolated from G-CSF mobilized haematopoietic stem cell
donors (Charite´ Hospital, Berlin), in accordance with the declaration of Helsinki.
These CD34þ cells were cultured in X-Vivo15 (Lonza) at 37 C in 5% CO2.
CD34þ progenitor cells were differentiated to immature dendritic cells by
granulocyte CSF, tumour necrosis factor TNF-a, granulocyte granulocyte-
macrophage CSF and interleukin-4 (Peprotech) stimulation at 1,000Uml 1 for 5
days of incubation. Mature dendritic cells were produced by stimulation for 2 days
with LPS at 500 ngml 1 (ref. 59). THP-1 cells (ATCC 8808120) were grown in
RPMI-1640 (PAA), 10% inactivated fetal bovine serum (PAA) and penicillin/
streptomycin (Sigma).
Titan wild type (Titan-WT) and the equivalent isolate with a deletion in the
US28 gene (Titan-DUS28) were kind gifts from Martine Smit (Division of
Medicinal Chemistry, University of Amsterdam, The Netherlands), and their
generation has been previously described60. TB40E with an SV40-GFP tag has been
described previously14,50. HFFs were infected at a predicted MOI of 0.1 based on
titration on HFF cells. For myeloid cells, MOIs were calculated by titration on
RPE-1 cells (ATCC CRL-4000). Monocytes and THP-1 were infected with all
HCMV viral isolates at a predicted MOI of 5, leading to B10% infected cells.
For Fig. 3b, virus stock was diluted so that monocytes were infected at MOIs of
5, 2.5, 1.25, 0.625, 0.5, 0.25, 0.1 and 0.05. In order to maintain a detectable number
of reactivation events, a proportional increase in the number of monocytes were
infected. For the above MOIs, the number of monocytes infected were: 5 104,
1 105, 2 105, 4 105, 5 105, 1 106, 1.5 106 and 3 106, respectively.
Treatment with F49A-FTP. Latently infected monocytes were treated with
F49A-FTP 24 h post infection, or 24 h after isolating the naturally latently infected
monocytes. In Supplementary Fig. 3a, where stated, this treatment was delayed
across the time course of latent infection. Based on pilot studies of titrations of
F49A-FTP (Supplementary Fig. 2a), all cell cultures were treated with 5 10 8M
F49A-FTP.
Quantifying reactivation events. Monocyte and CD34þ -derived dendritic cells
were co-cultured with 3 103 HFFs per cm2 of growth area in a 50:50 mixture of
DMEM and RPMI or DMEM and X-Vivo15 (Lonza), respectively. Cultures were
incubated for 2 weeks for experimental latency or 3 weeks for natural latency to
allow time for reactivation events to be clearly visualized, and then stained for IE
protein.
Quantifying cell survival. Cell death was quantiﬁed using Trypan blue staining in
a 1:20 dilution in PBS. Cells were immediately observed by light microscopy and
both white (live) and blue (dead) cells were counted. Cell survival was calculated as
the number of white cells as a percentage of total cells.
Immunoﬂuorescent staining for IE protein-positive cells. Cells were ﬁxed and
stained as described previously61. In brief, following ﬁxation in paraformaldehyde
and permeabilization in 70% ethanol, cells were washed in PBS and stained with
mouse anti-IE (Argene 11-003) diluted in PBS (1 in 1,000) followed by goat
anti-mouse (Alexaﬂuor 488) with Hoechst nuclear stain. Cell percentages were
calculated as the percentage of Hoechst-stained nuclei colocalizing with IE-positive
nuclei.
Lentivirus transduction of THP-1 cells. A US28 construct with an N-terminal
HA tag was kindly provided by Daniel Streblow (Oregan Health and Science
University). This construct was subcloned into the lentiviral vector (pHR-SIN
1253) that was provided by Paul Lehner (Cambridge Institute for Medical
Research) and was co-transfected with packaging and envelope plasmids into 293T
cells (ECACC 85120602). Lentivirus was harvested after 48 and 72 h and incubated
with THP-1 cells in the presence of polybrene for transduction of US28 expression.
Detection of US28 expression by immunoblot. THP-1 cells, transduced to
express HA-US28, were lysed in RIPA buffer (supplemented with 0.1% SDS, 2mM
EDTA and 1mM phenylmethylsulfonyl ﬂuoride). Nuclei and cell debris were
removed by centrifugation at 13,000 g for 10min at 4 C. Proteins were separated
on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes
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(Axygen, Corning). Incubations with primary and secondary antibodies were in 5%
skimmed milk for 1 h each at room temperature. To detect HA-US28, mouse
anti-HA antibody (1 mgml 1) (F-7 Santa Cruz Biotechnology) was used followed
by bovine anti-mouse horseradish peroxidase (Santa Cruz Biotech). Blots were
developed with the use of enhanced chemiluminescence (GE Healthcare) and
visualized with autoradiography ﬁlm. A full version of the blot in Fig. 2 can be seen
in Supplementary Fig. 5.
Homologous binding experiments on transfected COS-7 cells. 3 106 COS-7
cells (ATCC CRL-1651) were transfected with 20 mg of receptor cDNA (US28 or
CX3CR1) using the calcium precipitation method56 and transferred to 24-well
culture plates coated with poly-D-lysine 1 day after transfection. The number of
cells seeded per well was determined by the apparent expression efﬁciency of the
receptors and was aimed at obtaining 5–10% speciﬁc binding of the added
radioactive ligand (2.5 104 cells per well for US28 and 1 105 cells per well
for CX3CR1-expressing cells). At 2 days after transfection, cells were assayed by
competition binding for 3 h at 4 C using 10–15M 125I-CX3CL1 as well as
unlabelled CX3CL1 in 50mM HEPES buffer, pH 7.4, supplemented with 1mM
CaCl2, 5mM MgCl2 and 0.5 (w/v) bovine serum albumin (binding buffer)62. After
incubation, cells were washed twice in ice-cold binding buffer, supplemented with
0.5M NaCl. Experiments were performed in duplicate.
Homologous binding experiments on monocytes. Approximately 2 108
monocytes were infected with SV40-GFP-TB40E at an MOI of 5. At 4 days after
infection, monocytes were sorted for GFP-positive cells, yielding B5% of total
cells. Approximately 7 104 of these GFP-positive monocytes were seeded per well
to 96-well culture plates coated with poly-D-lysine. At 3 h after seeding, cells were
assayed by competition binding as described for COS-7 cells above. Determinations
were made in duplicate.
RT-qPCR analysis of viral and cellular gene expression. For RT-qPCR, RNA
was harvested using TRIzol reagent (Life Technologies) and isolated using RNeasy
mini kit (Qiagen), following the manufacturer’s instructions. UL138, IE and UL99
were quantiﬁed using a one-step RT-qPCR using Quantitect Virus kit (Qiagen) as
previously described12. UL138 was detected using the following primers and probe:
50-CTGGATACACGGTACACA-30 (forward), 50-TACGGGAATTCAGTGGAT
A-30 (reverse), and [cy5] 50-CCTGCGACGACTACACTATGAATACA-30 [BHQ2]
(probe). IE was detected using the following primers and probe: 50-GGGTA
TGTGTCTGAAAATGA-30 (forward), 50-GACTCTTATCAGAACACAACAA-30
(reverse), and [6FAM] 50-ATCTTCTTCTGCCGCTGCCTTA-30 [BHQ2] (probe).
UL99 was detected using the following primers and probe: 50-CGAACTCTGCA
AACGAATA-30 (forward), 50-GAGGGATGTTGTCGTAGG-30 (reverse), and
[cy3]50-CGTAGAGACACCTGGCGACC-30 [BHQ2] (probe). Samples were
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as described
previously12, using the following primers and probe: 50-CCCTTCATTGACCTC
AAC-30 (forward), 50-GGTGATGGGATTTCCATTG-30 (reverse), and [JOE]
50-CTCAGCCTTGACGGTGCCAT-30 [BHQ2].
CX3CR1 and US28 were detected using Quantitect SYBR Green RT-PCR Kit
(Qiagen), following the manufacturer’s instructions, and the following primers:
50-CTGCCTCTTAGACTTCTG-30 (forward), 50-GGCTATCACTCTGTAGAC-30
(reverse). US28 was detected using the following primers: for the forward
primer: 50-TCGCGCCACAAAGGTCGCATTG-30 , and for the reverse primer:
50-CGACACACCTCGTCGGACAGCG-30 . Values were calculated using the DDCT
method relative either to uninfected monocytes (for CX3CR1) or monocytes
immediately after infection with HCMV (for US28). Samples were normalized to
GAPDH, as described previously12.
Ethics statement. All human samples were obtained under ethical approval and
after approval of protocols from the Cambridgeshire 2 Research Ethics Committee
(REC reference 97/092) conducted in accordance with the Declaration of Helsinki.
Informed written consent was obtained from all of the volunteers included in this
study before providing blood samples and all experiments were carried out in
accordance with the approved guidelines.
Data availability. All relevant data are available from the authors on request.
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